Main histologic and treatment characteristics in patients with catastrophic progression to ESKD.
| Sex/Race/Age, yrs | ISN/RPS Class | eGFR | Time to ESKD, months | Treatment | Factors Associated With ESKD |
|---|---|---|---|---|---|
| F/H/42 | V | 110 | 36 | GC, AZA, AM, ACEI | Patient achieved complete remission for 24 months and then discontinued all medications to follow a naturopathic approach |
| M/W/26 | III | 137 | 23 | GC, MMF, AM, ACEI | Patient achieved complete remission at 12 months and then discontinued all medications to follow alternative treatments |
| F/B/41 | IV/V | 82 | 31 | GC, CYC, AM, MMF, ACEI | Severe interstitial inflammation and tubuloreticular inclusions |
| F/A/44 | IV/V | 61 | 11 | GC, AZA, AM, ACEI | Patient discontinued all medications after 3 months |
| F/B/26 | V | 88 | 25 | GC, MMF, AM, ACEI | Collapsing glomerulopathy |
| F/B/33 | IV | 111 | 12 | GC, CYC, AM, MMF | Patient did not achieve remission and discontinued all medications after 6 months |
| F/B/38 | IV | 81 | 6 | GC, MMF, AM, RTX | Extensive thrombotic microangiopathy |
| F/B/31 | IV | 61 | 36 | GC, CYC, MMF | Severe interstitial inflammation and tubuloreticular inclusions |
| M/W/24 | IV | 93 | 6 | GC, CYC, AM, TPE | Anti-GBM nephropathy (anti-GBM antibodies detected at disease onset) |
| F/H/37 | IV | 81 | 6 | GC, MMF, AM, RTX | Thrombotic microangiopathy (catastrophic APS) |
A: Asian patients; ACEI: angiotensin-converting enzyme inhibitor; AM: antimalarials; APS: antiphospholipid syndrome; AZA: azathioprine; B: Black patients; CYC: cyclophosphamide; eGFR: estimated glomerular filtration rate; ESKD: endstage kidney disease; F: female; GBM: glomerular basement membrane; GC: glucocorticoids; H: Hispanic patients; ISN/RPS: International Society of Nephrology/Renal Pathology Society; M: male; MMF, mycophenolate mofetil; RTX: rituximab; TPE: therapeutic plasma exchange; W: White patients.